Previous 10 | Next 10 |
DARE -PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include : Two Additional Portfolio Programs (DARE-GML and grant-funded DARE-...
Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST. Inv...
Organon ( NYSE: OGN ) said Ontruzant, a biosimilar of Roche's ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) cancer drug Herceptin, to treat Canadian adults with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC) was now availa...
Organon Canada launches Ontruzant®, a biosimilar of the reference biologic Herceptin®, providing patients in Canada with certain breast and gastric cancers with an additional therapeutic option at a lower cost Canada NewsWire KIRKLAND, QC , Nov. 14,...
Organon ( NYSE: OGN ) had declared $0.28/share quarterly dividend , in line with previous. Payable Dec. 15; for shareholders of record Nov. 14; ex-div Nov. 10. See OGN Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Organo...
Organon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer Canada NewsWire KIRKLAND, QC , Nov. 7, 2022 /CNW/ - Organon...
The following slide deck was published by Organon & Co. in conjunction with their 2022 Q3 earnings call. For further details see: Organon & Co. 2022 Q3 - Results - Earnings Call Presentation
Organon & Co. (OGN) Q3 2022 Earnings Conference Call November 03, 2022 8:30 AM ET Company Participants Jennifer Halchak – Vice President, Investor Relations Kevin Ali – Chief Executive Officer Matt Walsh – Chief Financial Officer Sand...
Merck ( MRK ) spinoff Organon & Co. ( NYSE: OGN ) rose after its Q3 2021 financials topped Street forecasts on Thursday, even as the company reported a decline in revenue for the second consecutive quarter. Revenue for the quarter fell ~4% YoY on a GAAP basis to ...
Organon press release ( NYSE: OGN ): Q3 Non-GAAP EPS of $1.32 beats by $0.22 . Revenue of $1.54B (-3.8% Y/Y) beats by $20M . Full year 2022 financial guidance ranges updated: Revenue range narrowed to $6.1 billion to $6.2 billion and reflects persisting for...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...